# JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

> **NCT06079983** · PHASE3 · RECRUITING · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 400 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** JSKN003
- **DRUG:** Capecitabine tablets
- **DRUG:** Gemcitabine hydrochloride for injection
- **DRUG:** Vinorelbine tartrate injection
- **DRUG:** Paclitaxel for injection (albumin-bound type)
- **DRUG:** Docetaxel injection
- **DRUG:** Eribulin mesylate injection

## Key facts

- **NCT ID:** NCT06079983
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2026-04-01
- **Final completion:** 2029-03-01
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06079983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06079983, "JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06079983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*